All Biopharma

The Precarious Pharmaceutical Supply Chain: To Reshore or Not to Reshore – Part I

The advent of COVID-19 has resurfaced the age old debate of reshoring to mitigate against potential quality issues in the pharma supply chain. With 80% of global API coming from China and India, there’s a massive reliance on these countries to deliver a secure, reliable and quality supply chain. Pharma’s Almanac asked Haig to write a piece on this, part 1 of which is below and part 2 will be published in the Q4 edition of Pharma’s Almanac with industry expert interviews.